Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...

For some, the issue with GLP-1 drugs like Ozempic and Mounjaro isn't getting access to these game-changing medications, but ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...

A SYSTEMATIC review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded ...

Nearly half of individuals consuming alcohol at baseline reduced their alcohol consumption following the initiation of AOMs.

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...

Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...

The medication’s primary mechanism involves mimicking glucagon-like peptide-1 (GLP-1), a naturally occurring hormone in the ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...